📊 Analysis 
BPMC:
Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers.
Market Prospects: Positive market response to Ayvakit's unique clinical profile.
CEO's Confidence: CEO's confidence in the company's future contributes to its momentum.
📈 Bullish Sentiment:
Entry Range: Suggested entry above the $83.00-$84.00 range.
Upside Target: Aiming for an upside in the $120.00-$125.00 range.
🌐 Note: Monitor BPMC's ongoing developments and market performance! 📊💹 #BPMC #Biotech #BullishSentiment 💊📈
BPMC:Financial Performance: 90% YoY growth in net-product revenues from U.S. sales of Ayvakit, a drug for certain cancers.
Market Prospects: Positive market response to Ayvakit's unique clinical profile.
CEO's Confidence: CEO's confidence in the company's future contributes to its momentum.
📈 Bullish Sentiment:
Entry Range: Suggested entry above the $83.00-$84.00 range.
Upside Target: Aiming for an upside in the $120.00-$125.00 range.
🌐 Note: Monitor BPMC's ongoing developments and market performance! 📊💹 #BPMC #Biotech #BullishSentiment 💊📈
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.